Spago Nanomedical Continues Recruitment in The Phase I/IIa Tumorad-01 Study Following Positive DMC Recommendation
Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends that the ongoing clinical phase I/IIa study Tumorad-01 with the drug candidate 177Lu-SN201 continues with parallel recruitment of two additional patients at the current dose level. The recommendation is based on an analysis of data from a total of 14 dosed patients across a broad spectrum of solid tumors,...
Read more








